SERA
Sera Prognostics Sets Stage for Commercial Success with Strong 2025 Performance
Sera Prognostics, a leading biotech company focused on preventing preterm birth, has made significant strides in advancing its commercial infrastructure and preparing for large-scale adoption of its innovative biomarker-based identification technology. According to the company's Q4 2025 financial results conference call transcript reported on March 18, 2026, Sera